Latest Insider Transactions at Ionis Pharmaceuticals Inc (IONS)
This section provides a real-time view of insider transactions for Ionis Pharmaceuticals Inc (IONS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IONIS PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IONIS PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2020
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
710
-1.04%
|
$35,500
$50.82 P/Share
|
|
Nov 24
2020
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
710
+1.03%
|
$27,690
$39.87 P/Share
|
|
Nov 24
2020
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,380
-7.25%
|
$119,000
$50.83 P/Share
|
|
Nov 24
2020
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,380
+6.76%
|
$92,820
$39.87 P/Share
|
|
Nov 24
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
4,320
-11.73%
|
$216,000
$50.83 P/Share
|
|
Nov 24
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,320
+10.5%
|
$168,480
$39.87 P/Share
|
|
Nov 24
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Direct |
2,590
-56.17%
|
$129,500
$50.83 P/Share
|
|
Nov 24
2020
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
2,590
+35.97%
|
$101,010
$39.87 P/Share
|
|
Nov 23
2020
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
3,200
-4.53%
|
$160,000
$50.12 P/Share
|
|
Nov 23
2020
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+4.33%
|
$124,800
$39.87 P/Share
|
|
Nov 23
2020
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,700
-26.0%
|
$535,000
$50.11 P/Share
|
|
Nov 23
2020
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,700
+20.64%
|
$417,300
$39.87 P/Share
|
|
Nov 23
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
19,000
-22.04%
|
$950,000
$50.11 P/Share
|
|
Nov 23
2020
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+17.81%
|
$741,000
$39.87 P/Share
|
|
Nov 23
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Direct |
11,600
-85.16%
|
$580,000
$50.11 P/Share
|
|
Nov 23
2020
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
11,600
+45.99%
|
$452,400
$39.87 P/Share
|
|
Nov 23
2020
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
500
-24.03%
|
$25,000
$50.0 P/Share
|
|
Nov 23
2020
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Indirect |
500
+19.37%
|
$19,500
$39.87 P/Share
|
|
Nov 03
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-31.59%
|
$690,000
$46.77 P/Share
|
|
Nov 03
2020
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.01%
|
$585,000
$39.87 P/Share
|
|
Oct 20
2020
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Direct |
2,889
-17.32%
|
$132,894
$46.86 P/Share
|
|
Oct 15
2020
|
Peter N Reikes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,778
+25.0%
|
-
|
|
Oct 15
2020
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,778
+25.0%
|
-
|